-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 14, the 2nd Shanghai International Biomedical Industry Week was grandly opened
in Shanghai.
Top experts, scholars and industry innovators shared their thoughts on innovation driving the development of the biomedical industry under a high level of openness, and the on-site topics focused on the themes of innovation linking the world, digitally empowering the industry, and building a human health community
.
Integration of the biomedical community
Integration of the biomedical communityFacing the future, how can Shanghai Power help build a community of human health and health? In the opening ceremony, three academicians of the Chinese Academy of Sciences, Chen Kaixian, Jiang Hualiang and Dong Chen, as well as Zhang Wenhong, director of the National Medical Center for Infectious Diseases and director of the Department of Infectious Diseases of Huashan Hospital affiliated to Fudan University, discussed this topic, analyzed the development power of Shanghai's biomedical industry, and provided suggestions for the integration of
Shanghai's construction of a biomedical community.
Academician Chen Kaixian, Academician Jiang Hualiang, Academician Dong Chen and Professor Zhang Wenhong
Academician Chen Kaixian, Academician Jiang Hualiang, Academician Dong Chen and Professor Zhang WenhongAcademician Chen Kaixian said that China has moved from imitation to independent innovation and development, and traditional medicine is actively seeking transformation and integration to integrate into mainstream medicine, such as promoting traditional Chinese medicine to go abroad, signing intergovernmental cooperation agreements with dozens of countries, widely used in more than 180 countries, and a number of standards have been adopted
by the European Union and the United States.
Will traditional fields be challenged by advanced technologies such as AI while transforming and merging? Academician Jiang Hualiang believes that with the current level of technological development, the application of AI in the pharmaceutical field cannot completely replace the innovative development model
of traditional drugs for the time being.
However, it is undeniable that AI technology has almost covered the entire process
from drug target development to clinical research and landing application.
For example, he said, in 2021, Zhangjiang Group and Shanghai Institute of Pharmaceutical Sciences initiated the establishment of the Zhangjiang AI Drug R&D Alliance to promote the cross-border integration
of AI and biomedicine.
At present, the innovation of Shanghai's biomedical industry has achieved some results, Academician Jiang Hualiang pointed out that from 2013 to November 22 this year, a total of 95 first-class new drugs were listed in China, and Shanghai accounted for nearly a quarter with 23, such as the recently launched new drug for type 2 diabetes, dociglipatin, and the Alzheimer's disease treatment drug mannarate
.
On the other hand, Academician Chen Kaixian believes that there are still few innovative drugs with new targets and new mechanisms of action, and the original innovation needs to be further strengthened
.
Finally, Academician Dong Chen said that innovation is for sharing, and science has no boundaries
.
He believes that in addition to the human health community, it is also necessary to establish a scientific community, promote scientific progress through exchanges and cooperation, and the goal of China's innovation is to solve the global patient health and medical needs
.
Innovation has no borders, and industry landing has borders
.
Shanghai is the advantage of industrial landing, and the participating experts believe that the smooth development of the Shanghai International Biomedical Industry Week can attract more industries to land in Shanghai
.
Driven by innovation with a global perspective
Driven by innovation with a global perspectiveBiomedical innovation is inseparable from global cooperation
.
Dominic Jordan, President of the International Federation of Pharmaceutical Sciences (FIP), highly recognized Shanghai's position in the international biomedical field, "Our shared vision is that people all over the world can access and benefit from safe, effective, high-quality and affordable medicines and pharmaceutical services, and the Shanghai biomedical industry is an important component of realizing this vision
.
" ”
Xue Min, Chairman of United Imaging Group, shared the innovation model of industry-university-research-medical integration that radiates around the world, and explored the establishment of in-depth integration and innovation
with hospitals, universities and research institutions.
He emphasized: "Focusing on the three attributes of strong medicine, strong science and technology, and strong strategy, and linking the world with innovation, the biomedical industry will surely usher in a 'golden window period'
.
" ”
Chairman of United Imaging Group Xue Min
Chairman of United Imaging Group Xue MinAt the specific operational level, Anna Tian, Senior Vice President and President of Merck China, pointed out that Merck is promoting drug innovation in China, integrating R&D, manufacturing and commercial operations, and establishing a new China development strategy with the theme of "Bright Future", such as its recent signing of a distribution agreement with Sinopharm on the import and distribution of the anti-new crown oral drug monoravir in China, promoting the new drug to benefit more Chinese patients
.
Anna Tian, Senior Vice President and President of Merck China
Anna Tian, Senior Vice President and President of Merck ChinaGoing back to the origins of innovation, 2013 Nobel laureate Thomas Soudhoff argued that science must be problem-oriented
.
Reviewing contemporary biomedical translational research, he noted that "deep biological understanding is a prerequisite for
drug development.
Without basic science, transformation is impossible
.
”
The biggest challenge in drug development is finding druggable targets
.
Thomas said that advanced science and technology in recent years have provided new ways to this challenge, such as cryo-EM, stem cell biology, RNA sequencing, proteomics and other new technologies, but also drive RNA therapy, gene editing, cell therapy and other new treatment modalities
.
Industrial transformation in the context of digitalization
Industrial transformation in the context of digitalizationIn the process of digitalization-enabled biomedical R&D and production, a number of digital transformation pioneers have emerged
.
Eight companies, including Insilico, Junshi Biologics and Boehringer Ingelheim, were awarded the first batch of digital transformation pioneer certificates
in the biomedical industry.
"The strong demand for medical and health care, the unbalanced distribution of medical resources, and the low efficiency of medical services are forcing the rapid development
of the digital transformation and upgrading of medical health.
" Wang Lei, Executive Vice President, International Business and China President of AstraZeneca, pointed out that digitalization empowers the entire medical industry, from drug development to clinical application
.
AstraZeneca has established the Medical Artificial Intelligence Innovation Center, the International Life Sciences Innovation Park, and entered into a strategic partnership with Tempus, a leader in artificial intelligence and precision medicine, to promote the development
of patient-centric digital innovative drugs.
Lei Wang, Executive Vice President, International Business and China President, AstraZeneca
Lei Wang, Executive Vice President, International Business and China President, AstraZenecaYang Guangzhong, academician of the Royal Academy of Engineering and founding director of the Institute of Medical Robotics of Shanghai Jiao Tong University, shared his thoughts
on digital medicine from three aspects: digital health, digital instruments and digital surgery.
He said that digital medicine is improving medical health, such as combining implantable devices and new drug research and development to jointly cope with chronic disease management, and the development of digitalization will also promote the widespread use of
surgical instruments, implanted instruments, and surgical robots.
Yang Guangzhong, academician of the Royal Academy of Engineering and founding director of the Institute of Medical Robotics of Shanghai Jiao Tong University
Yang Guangzhong, academician of the Royal Academy of Engineering and founding director of the Institute of Medical Robotics of Shanghai Jiao Tong UniversityTalking about the expectations for the transformation and upgrading of Shanghai's digital healthcare, Wang Lei hopes to combine pharmaceutical innovation, artificial intelligence, big data and smart healthcare, break down data barriers at all levels and institutions in the city, and combine electronic medical record follow-up and genetic big data to support the development of
overall innovative drugs.
As industry benchmarks in the field of digital transformation, pioneers such as Insilico will lead the digital transformation and upgrading of the industry and promote Shanghai's biomedical industry to a new level
.
